


# Accepted Manuscript

Improved outcomes in patients with retinal detachment following implementation of a silicone oil registry and phone call reminder system

Dahui Ma, MD, Wei Ma, MD, PhD, Xiuyun Liu, PhD, Jay M. Stewart, MD



PII: S2468-6530(19)30009-0

DOI: <https://doi.org/10.1016/j.oret.2019.01.013>

Reference: ORET 459

To appear in: *Ophthalmology Retina*

Received Date: 6 September 2018

Revised Date: 16 January 2019

Accepted Date: 18 January 2019

Please cite this article as: Ma D., Ma W., Liu X. & Stewart J.M, Improved outcomes in patients with retinal detachment following implementation of a silicone oil registry and phone call reminder system, *Ophthalmology Retina* (2019), doi: <https://doi.org/10.1016/j.oret.2019.01.013>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **Improved outcomes in patients with retinal detachment**  
2 **following implementation of a silicone oil registry and phone**  
3 **call reminder system**

4 Dahui Ma, MD,<sup>1,2</sup> Wei Ma, MD, PhD,<sup>1,3</sup> Xiuyun Liu, PhD,<sup>4</sup> Jay M Stewart, MD<sup>1</sup>

5

6 <sup>1</sup>Department of Ophthalmology, University of California, San Francisco,  
7 Department of Ophthalmology, San Francisco, CA

8 <sup>2</sup>Shenzhen Key Laboratory of Ophthalmology, Shenzhen Eye Hospital, Jinan  
9 University, School of Optometry, Shenzhen University

10 <sup>3</sup> State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun  
11 Yat-Sen University, Guangzhou, China

12 <sup>4</sup> University of California, San Francisco, Department of Physiological Nursing,  
13 San Francisco, CA

14

15 Corresponding author:

16 Jay M. Stewart, MD

17 University of California, San Francisco

18 Department of Ophthalmology

19 10 Koret Way, K301

20 San Francisco, CA 94143-0730

21 Tel. (415) 206-3123

22 jay.stewart@ucsf.edu

23

24

25 Financial Support: That Man May See, Inc., and Research to Prevent

26 Blindness

27 Conflict of Interest: no conflicting relationship exists for any author

28

29 Word count: 2,064

30

31 **Abstract**

32 *Purpose:* This retrospective study was performed to assess the clinical impact  
33 in reducing silicone-oil related complications such as keratopathy of a registry  
34 and appointment reminder system for patients with complicated retinal  
35 detachment (RD) who underwent pars plana vitrectomy (PPV) with silicone oil  
36 (SO) tamponade.

37 *Design:* Retrospective cohort study

38 *Participants:* A total of 87 eyes of 87 patients who received SO tamponade  
39 were included.

40 *Methods:* The study was carried out at Zuckerberg San Francisco General  
41 Hospital and Trauma Center (ZSFG). Patients were divided into those who  
42 received SO either before (control group, n=48) or after (treatment group,  
43 n=39) implementation of a SO registry and patient reminder system in 2014.

44 Patient records were reviewed to identify clinical characteristics and outcomes.

45 *Main Outcome Measures:* The primary outcome measure was the difference in  
46 the rate of loss to follow-up, before versus after the implementation of the  
47 registry and reminder system. Secondary outcomes were the duration of SO  
48 tamponade, keratopathy rate, and intraocular pressure (IOP) at the last visit  
49 before SO removal.

50 *Results:* Forty-eight patients were included in the control group, and thirty-nine  
51 in the treatment group. The number of patients lost to follow up was 23

52 (47.9%) in the control group versus six (15.4%) in the treatment group  
53 (p=0.0015). The mean duration before SO removal was  $79.6 \pm 91.7$  weeks in  
54 control group, and that of treatment group was  $36.3 \pm 31.5$  weeks (Mean  $\pm$  SD)  
55 (p=0.015). Keratopathy developed in 33.3% of patients in the control group  
56 and in 12.8% in the treatment group (p=0.0425). Mean IOP at last visit before  
57 SO removal was  $13.0 \pm 5.2$  mmHg (Mean  $\pm$  SD) in control group and  $13.3 \pm 7$   
58 mmHg (Mean  $\pm$  SD) in treatment group (p>0.05).

59 *Conclusions:* A phone call appointment reminder system for patients with  
60 complicated RD who underwent PPV and SO tamponade reduced the rate of  
61 loss to follow-up and the duration of silicone oil tamponade, correlating with a  
62 reduction in the rate of keratopathy.

63

64

65

66

67

68

69

70

71 **Introduction**

72

73 Complex retinal detachment (RD) associated with proliferative  
74 vitreoretinopathy (PVR), giant retinal tear (GRT), proliferative diabetic  
75 retinopathy (PDR), ocular trauma and other causes can lead to significant  
76 vision loss and even legal blindness. Since it was first described in 1962,<sup>1</sup>  
77 silicone oil (SO) has been demonstrated to be an effective intraocular  
78 tamponade and has become part of the standard technique for complex retinal  
79 detachment repair,<sup>2,3</sup> a frequent choice for vitreous replacement following pars  
80 plana vitrectomy (PPV) in these complex cases.<sup>4-7</sup> However, it is still not a  
81 perfect or ideal permanent vitreous replacement because of its possible  
82 complications such as keratopathy, glaucoma, and cataract due to long term  
83 exposure.<sup>8</sup> In clinical practice, although it may be necessary to leave SO in the  
84 vitreous cavity as long as possible in a small group of patients with unusually  
85 complex findings, for most patients, silicone oil is usually removed after 3-6  
86 months in order to avoid complications.<sup>9</sup> Therefore, once SO is implanted in  
87 the eye, the clinical status of the eye must be monitored carefully to detect any  
88 complications and determine the appropriate amount of time that the SO  
89 should remain in order to achieve the goal of lasting retinal reattachment. In  
90 other words, regular follow-up appointments are needed in order to allow the  
91 clinician to observe the patient and adjust the timing of intervention as needed.

92 Most SO-related complications relate to emulsification. Keratopathy, glaucoma  
93 and cataract are the main complications of concern. The main risk factor for  
94 emulsification is duration of SO tamponade, with occurrence from 5 to 24  
95 months after SO injection; in most cases, emulsification is detectable within the  
96 first year.<sup>10</sup> Because of the variability in time to emulsification, regular follow-up  
97 is the key to balancing the anatomical and functional status of the eye and  
98 complications due to SO emulsification. Missed appointments at the surgeon's  
99 office can lead to delay in treatment and unexpected complications. Although  
100 many factors interfere with patient follow-up,<sup>11</sup> the most common reason for  
101 missed appointments is that the patient simply forgets.<sup>12</sup> Thus, there are  
102 various strategies including email, phone calls, letters and text messages that  
103 have been used as reminders in order to reduce missed appointments.  
104 Several studies have found that a personal phone call reminder can improve  
105 adherence to follow-up.<sup>13-15</sup>

106 Recently, some studies have documented an improvement in patient care  
107 outcomes in ophthalmology with phone call reminders in areas such as  
108 glaucoma<sup>16,17</sup> diabetic retinopathy<sup>18</sup> and age-related macular degeneration.<sup>19</sup>  
109 To the best of our knowledge, no study has evaluated the efficacy of a registry  
110 and phone call intervention to improve the rates of adherence and treatment  
111 outcomes in patients with complicated RD receiving SO tamponade. The  
112 objective of this study was to evaluate the clinical significance of a follow-up

113 appointment reminder system for patients with complicated RD who underwent  
114 PPV with SO tamponade.

115

116 **Methods**

117 After approval by the Human Research Protection Program at the University of  
118 California, San Francisco and Zuckerberg San Francisco General Hospital and  
119 Trauma Center (ZSFG), we conducted a retrospective review of a  
120 prospectively collected cohort of complex RD patients who underwent PPV  
121 with SO injection at ZSFG between 2006 and 2017. Part-way through that time  
122 period, in 2014, the Department of Ophthalmology at ZSFG implemented a  
123 phone call follow-up appointment reminder system for patients receiving SO  
124 injection. Clinic staff created a prospective registry of all patients receiving  
125 silicone oil injection. Once the 6-month duration of silicone oil implantation was  
126 reached, staff tracked whether the patient attended their 6-month appointment  
127 and whether the SO removal surgery was scheduled and completed. This was  
128 in addition to standard call-backs for individual missed clinic appointments, as  
129 is utilized widely in our practice and in others. In the event that the patient did  
130 not attend follow-up visits, staff persisted to contact the patient by phone  
131 multiple times to reschedule the appointment and confirm attendance. Staff  
132 also actively communicated with surgeons to ensure that SO removal was  
133 arranged and completed.

134 For the retrospective review conducted in this study, patients with complex RD  
135 who underwent PPV with SO injection between 2006 and 2017 and maintained  
136 an attached retina for more than three months were included. Patients were  
137 divided into two groups according to the date on which the surgery was  
138 performed. The control group consisted of patients who underwent the  
139 procedure before 2014, prior to the implementation of the registry and phone  
140 call reminder system; the treatment group consisted of patients whose surgery  
141 was in 2014 or later, with the new system in use.

142 Parameters analyzed for the study included age, gender, indication for  
143 surgery, duration before SO removal, time to follow-up, occurrence of  
144 keratopathy, the no-show rate in the treatment group, and intraocular pressure  
145 (IOP) at the last visit before SO removal. The loss to follow-up rate was  
146 calculated and relates to patients who underwent PPV with SO injection who  
147 disappeared from follow-up for more than 6 months and did not return for SO  
148 removal at all throughout the entire study period (to the end of 2017).

149 Keratopathy was defined as corneal complications including band keratopathy,  
150 corneal decompensation, and corneal opacities. A no-show was defined as a  
151 patient who missed a scheduled appointment without having cancelled it  
152 ahead of time. Since there was no intentional tracking of the scheduled  
153 appointments in the control group, the no-show rate was only calculated for the  
154 treatment group.

155 Categorical variables were compared between the two groups using SPSS  
156 software (version 21, IBM, Armonk, NY, USA) for statistical analysis. An  
157 independent t-test was used to compare age and the duration before SO  
158 removal between the two groups. The Wilcoxon Mann-Whitney test was used  
159 to compare the gender of the two groups. Results were considered significant  
160 at  $p < 0.05$ .

161

## 162 **Results**

163 Patients with complex RD who underwent PPV and 5,000-centistoke SO  
164 injection by the same attending physician, assisted by rotating residents and  
165 fellows, in the ophthalmology department at Zuckerberg San Francisco  
166 General Hospital between January 27, 2006 and June 30, 2017 were included  
167 in the study. Out of these patients, 48 were included the control group (no  
168 phone call reminder), and 39 patients in the treatment group (with phone call  
169 reminder).

170 Baseline demographics were comparable between the two groups (Table 1).  
171 There was no significant difference in age and gender between the two  
172 groups. The median age in the control group was 54.4 [45.0-59.9] years, and  
173 that of the treatment group was 55.0 [42.5-60.2] years. The control group  
174 consisted of 36 men and 12 women, while there were 27 men and 12 women  
175 in the treatment group. The number of patients with complex RD associated

176 with PVR, PDR, ocular trauma, GRT, and other causes was 14, 12, 7, 5, 9  
177 respectively in the control group, and was 20, 9, 7, 3, and 0 respectively in the  
178 treatment group.

179 With regard to the primary outcome measure, the number of patients lost to  
180 follow up was 23 (47.9%) in the control group versus 6 (15.4%) in the  
181 treatment group ( $p=0.0015$ ) (Figure 1). The remainder in each group (25  
182 controls and 33 treatment eyes) underwent SO removal. The mean duration of  
183 SO in the eye before removal was  $79.6 \pm 91.7$  weeks in the control group, and  
184 in the treatment group it was  $36.3 \pm 31.5$  weeks (mean  $\pm$  SD) ( $p=0.015$ ) (Figure  
185 2A). Mean IOP at the last visit before SO removal in the control group was  $13.0$   
186  $\pm 5.2$  mm Hg (mean  $\pm$  SD) and in the treatment group was  $13.3 \pm 7$  mm Hg  
187 (mean  $\pm$  SD) ( $p>0.05$ ) (Figure 2B). There were 16 (33.3%) patients in the  
188 control group who developed keratopathy, while only 5 (12.8%) in the  
189 treatment group did ( $p=0.0425$ ) (Figure 3). Within the control group there was  
190 a trend toward longer duration of SO tamponade correlating with the  
191 development of keratopathy as an independent variable: the mean duration  
192 of SO tamponade was 118.2 weeks in eyes developing keratopathy versus  
193 60.1 weeks in eyes without keratopathy ( $p=0.09$ ); in the treatment group, the  
194 mean duration of SO was 28.2 weeks in eyes with keratopathy and 32.2 weeks  
195 in eyes without keratopathy ( $p=0.96$ ). In the treatment group, the number of  
196 appointments kept was 232, while the number of no-show visits was 30,  
197 yielding a no-show rate of 11.5% (30/262). Finally, 100% of patients in the

198 treatment group were able to be examined or reached by phone at least once  
199 during the post-operative period.

200

201 **Discussion**

202 To the best of our knowledge, this is the first study to evaluate the efficacy of a  
203 registry system with phone call intervention to improve the rates of adherence  
204 and treatment outcomes in patients with complicated RD undergoing PPV with  
205 SO tamponade. In our study, patients with complex RD after surgeries in the  
206 phone call reminder group were significantly more likely to adhere to the  
207 recommended schedule and keep their eye examination appointments when  
208 compared to patients without any tracking and intervention. This study found  
209 that the number of patients lost to follow-up markedly dropped after  
210 implementation of the registry and reminder system, from 23 (47.9%) to 6  
211 (15.4%). Loss to follow up may represent a broader problem in the  
212 management of vitreoretinal disease, as a recent study showed that the rate  
213 exceeded 20% after anti-vascular endothelial growth factor injections.<sup>20</sup> The  
214 results of the present study indicate that a phone call reminder call system can  
215 be an effective means of improving patient compliance with follow-up  
216 examinations and surgical treatment. These findings are supported by  
217 previous studies demonstrating that a personal phone call appointment  
218 reminder can improved adherence to follow-up appointments,<sup>13–15</sup> despite the

219 fact that there are various reasons for patients not adhering to a schedule of  
220 follow-up appointments.<sup>11,21-23</sup>

221 In this series, reducing the loss to follow-up rate improved patient safety and  
222 outcomes, largely by shortening the time that SO remained in the patients'  
223 eyes. Indeed, duration of SO tamponade has been shown to be the greatest  
224 risk factor for SO emulsification, which can lead to keratopathy, glaucoma, and  
225 cataract.<sup>10</sup> Keratopathy as one of the complications of SO tamponade declined  
226 significantly after implementation of the registry and reminder system, in  
227 conjunction with the reduced duration of SO in the eye in the treatment  
228 group.<sup>10</sup> IOP was not significantly different between the groups, possibly  
229 because it was able to be controlled with eyedrops in both groups. Cataract  
230 formation was not analyzed as an outcome measure in this study for two  
231 reasons. First, unlike keratopathy or glaucoma, cataract formation does not  
232 lead to a permanently poor outcome, since it can be addressed surgically at  
233 any point; second, many patients had cataract removal in combination with  
234 their retinal detachment repair or silicone oil removal procedures.

235 In this study we also determined the no-show rate in the treatment group.  
236 This may be an important index in that it represents not only the care of the  
237 patients in question but also the experience of the clinic population in general  
238 due to the negative impacts that no-shows have on clinic efficiency. The  
239 no-show rate of 11.5% achieved in the treatment group is similar to the goal of

240 10% that is often established as a target for efficiency and to avoid disruption  
241 of clinic operations.<sup>24</sup> This reinforces the added value to clinic efficiency  
242 brought about by the SO registry and reminder system and is consistent with  
243 prior reports showing that reminders can improve ophthalmic follow-up  
244 adherence.<sup>25,26</sup>

245 There are several limitations to this study. One is that the study describes a  
246 retrospective cohort without randomization. This was necessarily the case  
247 since it tracks the change in practice in our department in the management of  
248 patients with SO. As such, the number of patients is not matched between the  
249 groups. In addition, the study is limited by its small sample size and the fact  
250 that the assessment takes place at only one center. Also, ZSFG is a public,  
251 safety net hospital whose patient composition may overrepresent persons with  
252 socioeconomic challenges relative to the broader population, potentially  
253 limiting the generalizability of our results. On the other hand, the dramatic  
254 impact of the SO registry in improving outcomes in this particular patient  
255 population may suggest that benefits could be achieved even in settings with  
256 traditionally less difficulty in ensuring patient adherence to follow-up. Indeed,  
257 studies suggest that significant problems with follow-up exist in other,  
258 non-safety net populations with ophthalmic disease.<sup>20</sup>

259 Another limitation is in the scope of patient parameters analyzed, as they  
260 relate to follow-up compliance. It is possible that a more specific analysis of  
261 patient characteristics, such as socioeconomic status, extent of family support,

262 housing status, race or ethnicity, and retinal detachment complexity could  
263 identify additional factors affecting follow-up that could enable a more focused  
264 application of staff resources to ensure compliance in a subset of SO patients.

265 In the absence of such a targeted approach, our data supports implementation  
266 of a registry such as that in use at ZSFG.

267

## 268 **Conclusions**

269 In this study, we found that a patient registry and phone call follow-up  
270 appointment reminder system for patients receiving SO tamponade  
271 significantly improved attendance at follow-up appointments and reduced the  
272 duration of SO in patients' eyes. Patient outcomes were improved, most  
273 concretely by a reduction in the rate of keratopathy with the use of the registry.  
274 Further studies are indicated to evaluate the generalizability of these results to  
275 other patient populations.

276

## 277 **Figure Legends:**

278

279 Figure 1:

280 The loss to follow-up rates in the Control and Treatment groups. The number  
281 of patients lost to follow-up was 23 (47.9%) in the control group versus 6  
282 (15.4%) in the treatment group ( $p=0.0015$ ).

283

284 Figure 2:

285 (A) Mean duration before SO removal between the Treatment and Control  
286 groups, showing a significant difference ( $p=0.015$ ). (B) Mean IOP in the two  
287 groups, showing no significant difference ( $p>0.05$ ). Error Bar: Standard Error.  
288 SO: silicone oil; IOP: intraocular pressure.

289

290 Figure 3:

291 Keratopathy developed in 16 (33.3%) patients in the Control group, while only  
292 5 (12.8%) in the Treatment group did ( $p=0.0425$ ).

293

294

295 **References**

- 296 1. PA C, BECKER B, OKUN E, CANAAN S. The use of liquid silicone in retinal  
297 detachment surgery. *Arch Ophthalmol* 1962;68:590–599.
- 298 2. Lesnoni G, Rossi T, Nistri A, Boccassini B. Long-term prognosis after  
299 removal of silicone oil. *Eur J Ophthalmol* 2000;10:60–65.
- 300 3. Falkner CI, Binder S, Kruger A. Outcome after silicone oil removal. *Br J  
301 Ophthalmol* 2001;85:1324–1327.
- 302 4. Abrams GW, Azen SP, McCuen BW 2nd, et al. Vitrectomy with silicone oil or  
303 long-acting gas in eyes with severe proliferative vitreoretinopathy: results of  
304 additional and long-term follow-up. *Silicone Study report 11. Arch Ophthalmol*  
305 (Chicago, Ill 1960) 1997;115:335–344.
- 306 5. Ghosh YK, Banerjee S, Savant V, et al. Surgical treatment and outcome of  
307 patients with giant retinal tears. *Eye (Lond)* 2004;18:996–1000.
- 308 6. Castellarin A, Grigorian R, Bhagat N, et al. Vitrectomy with silicone oil  
309 infusion in severe diabetic retinopathy. *Br J Ophthalmol* 2003;87:318–321.

310 7. Szurman P, Roters S, Grisanti S, et al. Primary silicone oil tamponade in the  
311 management of severe intraocular foreign body injuries: an 8-year follow-up.  
312 *Retina* 2007;27:304–311.

313 8. Azen SP, Scott IU, Flynn HWJ, et al. Silicone oil in the repair of complex  
314 retinal detachments. A prospective observational multicenter study.  
315 *Ophthalmology* 1998;105:1587–1597.

316 9. Lou B, Yuan Z, He L, et al. The changes of retinal saturation after long-term  
317 tamponade with silicone oil. *Biomed Res Int* 2015;Epub 2015 Oct 18.

318 10. Toklu Y, Cakmak HB, Ergun SB, et al. Time course of silicone oil  
319 emulsification. *Retina* 2012;32:2039–2044.

320 11. Whiting PS, Greenberg SE, Thakore R V, et al. What factors influence  
321 follow-up in orthopedic trauma surgery? *Arch Orthop Trauma Surg*  
322 2015;135:321–327.

323 12. Neal RD, Hussain-Gambles M, Allgar VL, et al. Reasons for and  
324 consequences of missed appointments in general practice in the UK:  
325 questionnaire survey and prospective review of medical records. *BMC Fam*  
326 *Pract* 2005;6:47.

327 13. Sawyer SM, Zalan A, Bond LM. Telephone reminders improve adolescent  
328 clinic attendance: a randomized controlled trial. *J Paediatr Child Health*  
329 2002;38:79–83.

330 14. Haynes JM, Sweeney EL. The effect of telephone appointment-reminder  
331 calls on outpatient absenteeism in a pulmonary function laboratory. *Respir*  
332 *Care* 2006;51:36–39.

333 15. Macharia WM, Leon G, Rowe BH, et al. An overview of interventions to  
334 improve compliance with appointment keeping for medical services. *JAMA*  
335 1992;267:1813–1817.

336 16. Glanz K, Beck AD, Bundy L, et al. Impact of a health communication  
337 intervention to improve glaucoma treatment adherence. Results of the  
338 interactive study to increase glaucoma adherence to treatment trial. *Arch*  
339 *Ophthalmol (Chicago, Ill 1960)* 2012;130:1252–1258.

340 17. Kowing D, Messer D, Slagle S, Wasik A. Programs to optimize adherence  
341 in glaucoma. *Optometry* 2010;81:339–350.

342 18. Zangalli CS, Murchison AP, Hale N, et al. An Education- and  
343 Telephone-Based Intervention to Improve Follow-up to Vision Care in Patients  
344 With Diabetes: A Prospective, Single-Blinded, Randomized Trial. *Am J Med*  
345 *Qual* 2016;31:156–161.

346 19. Thompson AC, Thompson MO, Young DL, et al. Barriers to follow-up and  
347 strategies to improve adherence to appointments for care of chronic eye  
348 diseases. *Investig Ophthalmol Vis Sci* 2015;56:4324–4331.

349 20. Obeid A, Gao X, Ali FS, et al. Loss to Follow-Up in Patients with  
350 Proliferative Diabetic Retinopathy after Panretinal Photocoagulation or  
351 Intravitreal Anti-VEGF Injections. *Ophthalmology* 2018;125:1386-92.

352 21. Li Y-J, Xirasagar S, Pumkam C, et al. Vision insurance, eye care visits, and  
353 vision impairment among working-age adults in the United States. *JAMA*  
354 *Ophthalmol* 2013;131:499–506.

355 22. Elam AR, Lee PP. High-risk populations for vision loss and eye care  
356 underutilization: a review of the literature and ideas on moving forward. *Surv*  
357 *Ophthalmol* 2013;58:348–358.

358 23. Wagner LD, Rein DB. Attributes associated with eye care use in the United  
359 States: a meta-analysis. *Ophthalmology* 2013;120:1497–1501.

360 24. McMullen MJ, Netland PA. Lead time for appointment and the no-show  
361 rate in an ophthalmology clinic. *Clin Ophthalmol* 2015;9:513–516.


362 25. Lin H, Chen W, Luo L, et al. Effectiveness of a short message reminder in  
363 increasing compliance with pediatric cataract treatment: a randomized trial.  
364 *Ophthalmology* 2012;119:2463–2470.


365 26. Brannan SO, Dewar C, Taggerty L, Clark S. The effect of short messaging  
366 service text on non-attendance in a general ophthalmology clinic. *Scott Med J*  
367 2011;56:148–150.


368

**Table 1: Baseline patient characteristics**

	Control group		Treatment group		p-value
<b>Gender</b>					0.55
<b>Male (n)</b>	36		27		
<b>Female (n)</b>	12		12		
	Median	[IQR]	Median	[IQR]	
<b>Age (years)</b>	54.4	[45.0-59.9]	55.0	[42.5-60.2]	0.73
<b>Diagnosis</b>					
<b>PVR (n)</b>	14		20		
<b>PDR (n)</b>	12		9		
<b>GRT (n)</b>	5		3		
<b>Ocular trauma (n)</b>	7		7		
<b>Other (n)</b>	9		0		
PVR, proliferative vitreoretinopathy; PDR, proliferative diabetic retinopathy; GRT, giant retinal tear; IQR, interquartile range					







**Precis**

Implementation of a silicone oil registry and phone call reminder system improved rates of adherence to follow-up appointments and treatment outcomes in patients with complicated retinal detachment who underwent vitrectomy with silicone oil tamponade.